Myelodysplastic syndrome

• A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes Pending
  2025-521394-13-00 1 "Relapsed/refractory Acute Myeloid Leukemia or relapsed/refra"
• Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic S … Pending
  2026-525464-18-00 1 "Clonal Cytopenia of Undetermined Significance with SF3B1 mut"
• A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refrac … Recruiting
  2024-519537-29-00 1 2026-03-13 "Acute Myeloid Leukemia and Myelodysplastic Syndrome"
• A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and my … Recruiting
  2025-521299-76-00 7 2025-12-18 "Relapsed or refractory acute leukaemia or Myelodysplastic Sy"
• RVU120 Rollover Study Recruiting
  2025-521673-14-00 4 2025-12-03 "Relapsed / Refractory Metastatic or Advanced Solid Tumors"
• A Study of AG-946 in Participants With Anaemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS). Recruiting
  2022-500609-42-00 4 2023-02-24 "Anemia Due to Lower-Risk Myelodysplastic Syndromes"
• A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Recruiting
  2023-506145-38-00 3 2021-05-11 "Treatment of participants with MF, MDS, ET, or MDS/MPN"
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Recruiting
  2025-523544-12-00 5 2026-06-02 "Myelodysplastic neoplasms/syndromes (MDS)"
• Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS Recruiting
  2025-523396-38-00 9 2026-05-29 "Relapse or refractory (r/r) acute myeloid leukaemia (AML) an"
• Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantatio … Recruiting
  2025-521372-62-00 4 2026-01-29 "Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute "
• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans … Recruiting
  2023-507879-21-00 4 2026-01-19 "AML and MDS undergoing allogeneic Transplantation"
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 "Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia "
• Momelotinib in VEXAS syndrome Recruiting
  2024-519779-24-00 4 2025-11-25 "VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMA"
• A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting
  2024-519928-24-00 4 2025-08-21 "Myelodysplastic Syndrome"
• A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting
  2024-515098-93-00 5 2025-07-22 "Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leuk"
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 "Newly Diagnosed Higher Risk Myelodysplastic Syndrome"
• A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla … Recruiting
  2024-514341-10-00 1 2025-05-27 "Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or"
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b … Recruiting
  2024-519498-20-00 9 2025-05-13 "Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Sy"
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 "Hypomethylating agent (HMA) naive myelodysplastic syndromes "
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 "myelodysplastic neoplasms/syndromes (MDS)"
• A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Recruiting
  2024-513199-16-00 1 2025-02-04 "Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or"
• CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY AC … Recruiting
  2024-515737-14-00 3 2024-10-07 "Acute leukemia and myelodysplastic syndromes"
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l … Recruiting
  2023-504555-27-00 5 2023-11-28 "Myelodysplastic syndrome (MDS)"
• A Safety Study of PF-08046040/SEA-CD70 in Patients with Myeloid Malignancies Recruiting
  2023-506945-42-00 1 2022-01-21 "Acute myeloid leukaemia"

Showing 1–24 of 51 trials